Sec Form 13D Filing - He Wei-Wu filing for CASI PHARMACEUTICALS HLDGS INC (CASI) - 2021-02-03

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

SCHEDULE 13D

 

Information to be included in statements filed pursuant to § 240.13d-1(a) and amendments thereto filed pursuant to § 240.13d-2(a)

(Amendment No. 4)

 

CASI Pharmaceuticals, Inc.

(Name of Issuer)

 

Common Stock, $.01 par value

(Title of Class of Securities)

 

14757U 109

(CUSIP Number)

 

Wei-Wu He Ph.D.

Emerging Technology Partners LLC

ETP Global Fund L.P.

4919 Rebel Ridge Dr.

Sugar Land, TX 77478

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

 

February 1, 2021

(Date of Event Which Requires Filing of This Statement)

  

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

 

Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

CUSIP NO. 14757U 109

	1		NAME OF REPORTING PERSON
				ETP Global Fund L.P.
	2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP															(a) ¨
																		(b) ¨
	3		SEC USE ONLY
	4		SOURCE OF FUNDS
				WC
	5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)															¨
	6		CITIZENSHIP OR PLACE OF ORGANIZATION
				DELAWARE
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				7		SOLE VOTING POWER
							0
				8		SHARED VOTING POWER
							8,766,914 (1)
				9		SOLE DISPOSITIVE POWER
							0
				10		SHARED DISPOSITIVE POWER
							8,766,914 (1)
	11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
				8,766,914
	12		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES															¨
	13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
				7.00%
	14		TYPE OF REPORTING PERSON
				PN

 

(1) Includes 1,234,567 shares issuable upon the exercise of warrants.

 

 

CUSIP NO. 14757U 109 

	1		NAME OF REPORTING PERSON
				EMERGING TECHNOLOGY PARTNERS, LLC
	2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP															(a) ¨
																		(b) ¨
	3		SEC USE ONLY
	4		SOURCE OF FUNDS
				WC
	5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)															¨
	6		CITIZENSHIP OR PLACE OF ORGANIZATION
				DELAWARE
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				7		SOLE VOTING POWER
							0
				8		SHARED VOTING POWER
							9,207,986 (2)
				9		SOLE DISPOSITIVE POWER
							0
				10		SHARED DISPOSITIVE POWER
							9,207,986 (2)
	11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
				9,207,986
	12		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES															¨
	13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
				7.36%
	14		TYPE OF REPORTING PERSON
				OO

 

(2) Includes 1,234,567 shares issuable upon the exercise of warrants.

 

 

CUSIP NO. 14757U 109 

	1		NAME OF REPORTING PERSON
				WEI-WU HE, Ph.D.
	2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP															(a) ¨
																		(b) ¨
	3		SEC USE ONLY
				OO
	4		SOURCE OF FUNDS
	5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)															¨
	6		CITIZENSHIP OR PLACE OF ORGANIZATION
				UNITED STATES
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				7		SOLE VOTING POWER
							12,394,008 (3)
				8		SHARED VOTING POWER
							9,207,986 (4)
				9		SOLE DISPOSITIVE POWER
							12,394,008 (3)
				10		SHARED DISPOSITIVE POWER
							9,207,986 (4)
	11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
				21,601,994
	12		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES															¨
	13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
				16.26%
	14		TYPE OF REPORTING PERSON
				IN

 

(3) Includes 7,710,014 shares issuable upon the exercise of options.

(4) Includes 1,234,567 shares issuable upon the exercise of warrants.

 

 

CUSIP NO. 14757U 109

 

This Amendment No. 4 (the “Amendment No. 4”) amends and supplements the original Schedule 13D filed with the Securities and Exchange Commission on January 12, 2018 (the “Schedule 13D”) as amended by Amendment No. 1 to the Schedule 13D filed on April 4, 2018 (the “Amendment No. 1”), Amendment No. 2 filed with the SEC on March 24, 2020 (the “Amendment No. 2”) and Amendment No. 3 filed with the SEC on July 29, 2020   (the “Amendment No. 3”). Amendments No. 1, 2 and 3 were filed by ETP Global Fund L.P. (“ETP Global”), a Delaware limited partnership, Emerging Technology Partners, LLC (“ETP”), a Delaware limited liability company, as the general partner of ETP Global, and Wei-Wu He, Ph.D., as founder and managing member of each of ETP and ETP Global. Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” The Schedule 13D relates to the shares of common stock, $.01 par value per share (the “Common Stock”) of CASI Pharmaceuticals, Inc. (the “Issuer”). Except as amended hereby, the disclosure in the Schedule 13D remains in effect.

 

Items 4 and 5 of the Schedule 13D are hereby amended and supplemented as follows:

 

Item 4.

Purpose of Transaction.

 

The Reporting Person is filing this Amendment No. 4 to Schedule 13D to report the vesting of options exercisable for 4,000,000 shares of Common Stock within 60 days of the date hereof. The options have an exercise price of $2.85 per share and were awarded by the Issuer in connection with equity compensation granted to Dr. He in connection with his services as Chief Executive Officer.

 

The information set forth in Item 5 below is incorporated by reference herein.

 

Item 5.

Interest in Securities of the Issuer  .

 

The aggregate percentage of Shares reported owned by each Reporting Person is based upon 123,943,829 shares of Common Stock outstanding as of February 1, 2021.

  

A.	ETP Global

 

	(a)	As of the close of business on February 1, 2021, ETP Global beneficially owned 8,766,914 shares of Common Stock, including 1,234,567 shares underlying warrants exercisable within 60 days hereof.
		Percentage: Approximately 7.00%

  

	(b)	1. Sole power to vote or direct vote: 0 2. Shared power to vote or direct vote:  8,766,914 3. Sole power to dispose or direct the disposition: 0 4. Shared power to dispose or direct the disposition:   8,766,914
	(c)	ETP Global has not entered into any transactions in the shares during the past 60 days.

 

 

B.

ETP

 

	(a)	ETP, as the general partner of ETP Global, may be deemed the beneficial owner of the 8,766,914 shares of Common Stock including 1,234,567 shares underlying the warrants beneficially owned by ETP Global and exercisable within 60 days hereof.  In addition, ETP is the direct beneficial owner of 441,072 shares.
		Percentage: Approximately 7.36%

 

(b)

1. Sole power to vote or direct vote: 0 2. Shared power to vote or direct vote: 9,207,986 3. Sole power to dispose or direct the disposition: 0 4. Shared power to dispose or direct the disposition:  9,207,986

 

(c)

ETP has not entered into any transactions in the shares during the past 60 days.

 

C.	Wei-Wu He, Ph.D.

 

< td style="padding-right: 0.8pt; text-align: justify"> 

	(a)	Dr. He may be deemed the beneficial owner of 12,394,008  shares of Common Stock, including  7,710,014 shares of Common Stock issuable upon the exercise of stock options within 60 days hereof.  In addition, as founder and managing member of each of ETP and ETP Global, Dr. He may be deemed the indirect beneficial owner of the 9,207,986 shares of Common Stock owned by ETP and ETP Global, including 1,234,567 shares underlying the warrants beneficially owned by ETP Global and exercisable within 60 days hereof.
		Percentage: Approximately 16.26%

  

(b)

1. Sole power to vote or direct vote: 12,394,008 2. Shared power to vote or direct vote:  9,207,986 3. Sole power to dispose or direct the disposition:  12,394,008 4. Shared power to dispose or direct the disposition:  9,207,986

 

(c)

On December 22, 2020, the Reporting Person made a gift of 380,000 shares of Common Stock to a charitable foundation. Except as set forth herein,  Dr. He has not entered into any transactions in the shares during the past 60 days.

 

The filing of this Schedule 13D shall not be construed as an admission that the Reporting Persons are, for purposes of Section 13(d) of the Act, the beneficial owners of any of the shares reported herein. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

 

(d)

No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares.

 

(e)

Not applicable.

 

Item 7.

Material to be Filed as Exhibits.

 

99.1

Joint Filing Agreement by and among ETP Global Fund LLP, Emerging Technology Partners LLC and Wei-Wu He, Ph.D.  dated January 11, 2018 (incorporated by reference from Exhibit 99.1 to the Schedule 13D filed on January 12, 2018)

 

 

SIGNATURES

 

After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Dated: February 3, 2021

 

	ETP GLOBAL FUND L.P.
	By:	EMERGING TECHNOLOGY PARTNERS, LLC General Partner
	By:	/s/ Wei-Wu He, Ph.D.
		Name:	Wei-Wu He, Ph.D.
		Title:	Managing Member

 

	EMERGING TECHNOLOGY PARTNERS, LLC
	By:	/s/ Wei-Wu He, Ph.D.
		Name:	Wei-Wu He, Ph.D.
		Title:	Managing Member

 

	/s/ Wei-Wu He, Ph.D.
	Wei-Wu He, Ph.D.